Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP698039.RAJadymY3db6xqikatKI6wAeBD8FeVZNtbm95GN7xgIfE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP698039.RAJadymY3db6xqikatKI6wAeBD8FeVZNtbm95GN7xgIfE130_assertion type Assertion NP698039.RAJadymY3db6xqikatKI6wAeBD8FeVZNtbm95GN7xgIfE130_head.
- NP698039.RAJadymY3db6xqikatKI6wAeBD8FeVZNtbm95GN7xgIfE130_assertion description "[Treatment of metastatic disease has improved significantly with the addition of several new agents, including tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and yttrium-90-DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and lutetium-177-DOTA octreotate.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP698039.RAJadymY3db6xqikatKI6wAeBD8FeVZNtbm95GN7xgIfE130_provenance.
- NP698039.RAJadymY3db6xqikatKI6wAeBD8FeVZNtbm95GN7xgIfE130_assertion evidence source_evidence_literature NP698039.RAJadymY3db6xqikatKI6wAeBD8FeVZNtbm95GN7xgIfE130_provenance.
- NP698039.RAJadymY3db6xqikatKI6wAeBD8FeVZNtbm95GN7xgIfE130_assertion SIO_000772 21388967 NP698039.RAJadymY3db6xqikatKI6wAeBD8FeVZNtbm95GN7xgIfE130_provenance.
- NP698039.RAJadymY3db6xqikatKI6wAeBD8FeVZNtbm95GN7xgIfE130_assertion wasDerivedFrom befree-20140225 NP698039.RAJadymY3db6xqikatKI6wAeBD8FeVZNtbm95GN7xgIfE130_provenance.
- NP698039.RAJadymY3db6xqikatKI6wAeBD8FeVZNtbm95GN7xgIfE130_assertion wasGeneratedBy ECO_0000203 NP698039.RAJadymY3db6xqikatKI6wAeBD8FeVZNtbm95GN7xgIfE130_provenance.